Skip to content
DataLookout
Menu

DIAN-TUNCT05269394

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

StatusActive, Not Recruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 13 versions: 11 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 20 words Show 4 more changesShow less
    • Trial sites reduced: 36 → 31 locations
    • Secondary endpoints: details revised at 3 of 7 entries
    • Collaborators: details revised at 1 of 4 entries
    • Publications: details revised at 12 of 12 entries
  2. Minor Study sites revised (36)v11
  3. Minor Study sites: 38 to 36v10
  4. Minor Site details revised at 3 of 38 sitesv9
  5. Notable Primary completion date: Jul 2027 to Apr 2028v7 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 168 to confirmed 197
    • Study completion date: Oct 2027 to Jul 2028
    • Site details revised at 38 of 38 sites
Show 5 earlier versionsHide 5 earlier versions
  1. Minor Study sites: 39 to 38v6
  2. Minor Site details revised at 2 of 39 sitesv5
  3. Minor Site details revised at 4 of 39 sitesv4
  4. Minor Study sites: 40 to 39v3
  5. Minor Site details revised at 4 of 40 sitesv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

The primary end point is the change from Week 24 to Week 104 and Week 208 in tau PET in the Symptomatic Population (Cohort 1).
Timeframe: Weeks 24, 104, and 208

Secondary (7)

Symptomatic Population (Cohort 1): Key Secondary: Change from Week 24 to Week 208 in Clinical Dementia Scale - Sum of Boxes (CDR-SB).
Asymptomatic Population (Cohort 2): Key Secondary: Change from Week 0 to Week 104 and Week 208 in CSF ptau217/total tau
Symptomatic Population (Cohort 1): Change from Week 24 to Week 104 and Week 208 in the cognitive composite score
Symptomatic Population (Cohort 1): Change from Week 0 to Week 24 in amyloid PET
Asymptomatic Population (Cohort 2): Change from Week 0 to Week 52 in CSF ptau217/total tau
Show 2 moreShow less
Symptomatic population (Cohort 1): Change from Week 24 to Week 104 and Week 208 in CSF neurofilament light chain (NfL)
Asymptomatic Population (Cohort 2): Change from Week 52 to Week 104 and Week 208 in CSF neurofilament light chain (NfL)

Arms and interventions

E2814 plus lecanemabExperimental

Symptomatic Population (Cohort 1) At Week 0, participants will receive open-label lecanemab administered intravenously for the full treatment period. At Week 24, participants randomized to E2814 will receive intravenously in a blinded fashion for the remainder of their treatment period. Asymptomatic Population (Cohort 2) At Week 0, participants randomized to E2814 will receive intravenously in a blinded fashion for the full treatment period. At Week 52, all participants will initiate open-label lecanemab administered intravenously for the remainder of their treatment period.

Matching placebo (E2814) plus lecanemabPlacebo comparator

Symptomatic Population (Cohort 1) At Week 0, participants will receive open-label lecanemab administered intravenously for the full treatment period. At Week 24, participants randomized to E2814 placebo will receive placebo intravenously in a blinded fashion for the remainder of their treatment period. Asymptomatic Population (Cohort 2) At Week 0, participants randomized to E2814 placebo will receive placebo intravenously in a blinded fashion for the full treatment period. At Week 52, all participants will initiate open-label lecanemab administered intravenously for the remainder of their treatment period.

Drugs: E2814, Lecanemab, Matching Placebo (E2814)

Sites

31 sites in 15 countries

United States 12, Canada 3, Australia 2, Germany 2, Italy 2, Argentina 1, Brazil 1, Colombia 1, Ireland 1, Japan 1, Mexico 1, Netherlands 1, Puerto Rico 1, Spain 1, United Kingdom 1